Published on June 27, 2012 at 1:50 AM
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused
on the research, development and commercialization of drugs for the
treatment of various forms of cancer, today announced that it has
completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR,
a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity
studies measure the ability of a drug to destroy cancer cells in vitro.
The results of the study showed that Adva-27a is significantly more
effective at killing Multidrug Resistant Small Cell Lung Cancer cells
than Etoposide, the current commonly used drug for this type of cancer.
This is the second form of Multidrug Resistant Cancer that Adva-27a has
shown effectiveness against. The first, which we had announced on July
11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.
"These findings are very interesting," said Dr. Steve N. Slilaty,
Sunshine's President and CEO. "Cancer cells become resistant to
anti-tumor drugs by overproducing a certain type of trans-membrane
proteins called ABC Transporters. These trans-membrane proteins bind and
transport drugs from the intracellular milieu to the outside of cancer
cells thereby making them resistant. Of the approximately 49 ABC
Transporters identified to date, two are most often found in Multidrug
Resistant Cancer: MDR1 and MRP1. The MCF-7/MDR Multidrug Resistant
Breast Cancer cell line, which we had previously announced overproduces
MDR1 while the H69AR Multidrug Resistant Lung Cancer cell line test in
the present study overproduces MRP1. It is remarkable that our Adva-27a
is able to overcome both of these resistance proteins," he added.
Source: Sunshine Biopharma Inc.